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Review
Methylmercury (MeHg) is a widespread and 
particularly toxic form of mercury (Hg). It 
results from the conversion of inorganic Hg to 
a methylated form by aquatic micro  organisms 
and can bioaccumulate in the aquatic food 
web. Dietary intake of MeHg, primarily 
through ingestion of contaminated fish and 
seafood, is recognized as a significant public 
health concern, primarily because of its well-
studied neurodevelopmental toxicity in fetuses 
and children. However, a growing body of 
evidence suggests that MeHg exposure may 
also lead to increased risks of adverse cardio-
vascular impacts in exposed populations.
In a comprehensive review of MeHg-
related health effects in 2000, the National 
Research Council (NRC) concluded that 
neuro  developmental impacts from prenatal 
MeHg exposures are the most sensitive and 
best-  documented end points (NRC 2000). The 
report also found limited evidence of adverse 
cardiovascular effects at similar levels of expo-
sure but did not reach firm conclusions on the 
cardiovascular impact of MeHg intake.
Since the publication of the NRC 
report, the U.S. Environmental Protection 
Agency (EPA) benefits assessments of 
rules controlling Hg emissions, such as 
the Clean Air Mercury Rule, have quanti-
fied neurodevelopmental benefits of reduc-
ing MeHg exposures to fetuses and children 
(U.S. EPA 2005). [For a diagram outlin-
ing the U.S. EPA’s benefits assessment pro-
cess, see Supplemental Material, Figure 1 
(doi:10.1289/ehp.1003012).] However, Rice 
et al. (2010) developed a probabilistic analysis 
that characterized the plausible distribution 
of health and economic benefits associated 
with a reduction in MeHg exposure and 
reported that 80% of the benefits were asso-
ciated with reductions in fatal heart attacks, 
and the remainder with IQ gains. Therefore, 
omitting these effects, if real, could result in 
a significant downward bias on the economic 
value of benefits ascribed to rules that con-
trol Hg emissions. Other assessments have 
reviewed the evidence for cardiovascular risk 
from MeHg exposure (Mozaffarian 2009; 
Stern 2005) and the balance of cardiovascular 
risks and benefits from MeHg exposure in 
conjunction with fish intake (Mozaffarian and 
Rimm 2006). However, previous assessments 
have not addressed the full range of poten-
tial cardiovascular health effects and have not 
focused on the development of dose–  response 
relationships between MeHg and these indi-
vidual cardiovascular effects.
In January 2010, the U.S. EPA convened 
a workshop in Washington, DC, to review 
the current science concerning cardiovascu-
lar impacts of MeHg exposures and to elicit 
recommendations about whether these effects 
should be included in benefits assessments of 
future Hg rules [for a list of questions posed 
by the U.S. EPA to workshop participants, 
see Supplemental Material (doi:10.1289/
ehp.1003012)]. The invited panel consisted of 
nine individuals, all coauthors of this article, 
with expertise spanning epidemiology, clinical 
medicine, toxicology, risk and exposure assess-
ment, biostatistics, and uncertainty analysis.
This article discusses the current litera-
ture and presents the recommendations of 
the assembled panel. In brief, we recommend 
the development of a dose–response function 
relating MeHg exposures with myocardial 
infarction (MI), for use in regulatory benefits 
analyses of future rules targeting Hg emissions.
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Ba c k g r o u n d: The U.S. Environmental Protection Agency (U.S. EPA) has estimated the   neurological 
benefits of reductions in prenatal methylmercury (MeHg) exposure in past assessments of rules con­
trolling mercury (Hg) emissions. A growing body of evidence suggests that MeHg exposure can also 
lead to increased risks of adverse cardiovascular impacts in exposed populations.
da t a e x t r a c t i o n: The U.S. EPA assembled the authors of this article to participate in a workshop, 
where we reviewed the current science concerning cardiovascular health effects of MeHg exposure 
via fish and seafood consumption and provided recommendations concerning whether cardio­
vascular health effects should be included in future Hg regulatory impact analyses.
da t a synthesis: We found the body of evidence exploring the link between MeHg and acute myo­
cardial infarction (MI) to be sufficiently strong to support its inclusion in future benefits analyses, 
based both on direct epidemiological evidence of an MeHg–MI link and on MeHg’s association 
with intermediary impacts that contribute to MI risk. Although additional research in this area 
would be beneficial to further clarify key characteristics of this relationship and the biological 
mechanisms that underlie it, we consider the current epidemiological literature sufficiently robust to 
support the development of a dose–  response function.
co n c l u s i o n s: We recommend the development of a dose–  response function relating MeHg expo­
sures with MIs for use in regulatory benefits analyses of future rules targeting Hg air emissions.
key w o r d s : cardiovascular, dose–response function, health impact analysis, mercury, methyl­
mercury, myocardial infarction. Environ Health Perspect 119:607–614 (2011).  doi:10.1289/
ehp.1003012 [Online 10 January 2011]Roman et al.
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Background
Hg fate and transport. Hg is present in most 
natural materials, including soils, coal, and 
minerals. It is released to the earth’s atmo-
sphere naturally from crustal materials, includ-
ing volcanic action, and from anthropogenic 
processes such as combustion of coal, waste 
combustion, and smelting. During atmo-
spheric transport, chemical reactions slowly 
convert elemental Hg to divalent forms that 
can bind to particulate matter. Both divalent 
Hg and particulate Hg are deposited from the 
atmosphere onto water bodies, where micro-
organisms and chemical processes can con-
vert a small proportion of the Hg to MeHg, 
which then bioaccumulates in fish. The most 
common route of MeHg exposure in humans 
is the consumption of marine and freshwater 
fish (Swain et al. 2007; U.S. EPA 1997).
Measuring Hg exposure. Human MeHg 
exposures are often assessed through the use 
of biomarkers, which serve as a surrogate 
for the biologically relevant internal dose of 
MeHg (NRC 2000). Three main biomarkers 
are commonly reported in the literature to 
assess MeHg exposures: blood Hg, hair Hg, 
and toenail Hg.
Whole-blood Hg is more closely correlated 
with ingested dose than is hair Hg, the other 
commonly employed biomarker of MeHg 
exposure (Budtz-Jørgensen et al. 2004), and 
generally reflects short-term exposures [the 
average half-life of MeHg in blood is 50 days 
(NRC 2000)]. Blood Hg concentrations meas-
ured at a specific point in time reflect contribu-
tions from both recent exposures, which may 
be increasing if intake is ongoing, and older 
exposures whose relative contribution decreases 
over time. In populations with frequent, regu-
lar patterns of fish consumption, blood Hg can 
reflect a steady-state concentration and there-
fore could be an accurate measure of average 
intake over time (NRC 2000). In populations 
with infrequent or irregular fish consumption, 
this steady-state assumption may be inappro-
priate, and a single measure of blood may not 
provide enough information to assess the mag-
nitude or timing of the exposures that contrib-
ute to the total blood Hg concentration.
Although whole-blood Hg is well cor  related 
with MeHg exposure among populations who 
regularly consume fish, whole-blood Hg also 
reflects inorganic Hg, some of which arises 
from dental amalgams and some from dem-
ethylation of MeHg. MeHg is preferentially 
bound in the red blood cells (RBCs), whereas 
inorganic Hg distributes more evenly between 
RBCs and plasma. Thus, RBC Hg can be a 
more precise biomarker for MeHg, especially 
in populations with dental amalgams and 
low MeHg exposure (Berglund et al. 2005). 
However, RBC Hg has been less commonly 
reported than whole-blood Hg, and intake–
biomarker relationships using RBC Hg have 
not been extensively investigated.
Hair Hg can provide some indication of 
both the magnitude and timing of exposures. 
The incorporation of Hg into the growing 
hair follicle is assumed to be directly pro-
portional to the blood concentration, with a 
delay of 1–2 months between MeHg intake 
and measurement in the visible proximal hair 
shaft (Budtz-Jørgensen et al. 2004; NRC 
2000). The relationship between location 
along the hair strand and timing of exposure 
can be ascertained by assuming a constant 
rate of hair growth; for example, a growth rate 
of 1.1 cm per month is commonly assumed 
(NRC 2000). Limitations of hair as an Hg 
biomarker include interindividual variability 
in the pharmacokinetics of Hg uptake from 
blood to hair shaft, inter- and intraindividual 
variability in hair growth rate, impact of hair 
treatment on hair Hg levels extraneous to the 
proximal end of the hair shaft, and the fact 
that the hair compartment is kinetically dis-
tant from ingestion and the target organ com-
partment (NRC 2000; Ohba et al. 2008).
Toenail Hg can be an indicator of average 
exposure over time (Rees et al. 2007). Garland 
et al. (1993) analyzed toenail Hg from two sets 
of clippings that were taken 6 years apart and 
reported a high level of reproducibility, which 
suggests that this biomarker can be represen-
tative of long-term exposure. Toenail clip-
pings represent several weeks of nail growth 
that correspond to intake over the previous 
3–12 months (Ohno et al. 2007; Rees et al. 
2007). However, the specific toxicokinetics 
of Hg uptake from the blood to the nail bed 
are not well understood. In addition, toenails 
suffer from some of the same shortcomings 
as hair (i.e., kinetically distant from ingestion 
and from the target organ, as well as potential 
interindividual variability in nail growth).
Workshop Findings and 
Near‑Term Recommendations
The consensus finding of the workshop par-
ticipants in support of an MeHg–MI dose– 
response function was based on a thorough 
consideration of available evidence, as dis-
cussed below. We have also developed a num-
ber of detailed recommendations that could 
be implemented in the near term to facilitate 
the development of a dose–  response function.
Likelihood of a causal relationship. We 
assessed the causal relationship between MeHg 
exposure and an increased risk of cardio  vascular 
health effects by evaluating the plausibility of 
biological mechanisms for the cardiovascular 
toxicity of MeHg and weighing the strength of 
the human, animal, and in vitro studies link-
ing MeHg with cardiovascular health impacts. 
Table 1 summarizes our assessment of the 
strength of the evidence presented in the lit-
erature evaluating MeHg and several cardio-
vascular health effects. We used professional 
judgment in our qualitative evaluations of the 
strength of evidence associated with each effect. 
Some of these effects represent clinical out-
comes (e.g., hypertension and MI), whereas 
others are intermediary effects that may con-
tribute to the progression of heart disease [e.g., 
oxidative stress, atherosclerosis, and decreased 
heart rate variability (HRV)]. Our examination 
of the evidence linking MeHg with these inter-
mediary effects, as described below, provides 
additional information to evaluate the plausi-
bility of the associations between MeHg and 
clinical cardiovascular disease.
Oxidative stress. MeHg exposure can cause 
oxidative stress, which is an early biological 
response that can produce vascular endothe-
lial cell damage by promoting inflammation 
and vasoconstriction as well as lipid peroxida-
tion through the generation of reactive oxygen 
species (ROS) (Grotto et al. 2009). Oxidative 
stress can lead to the development of cardio-
vascular disease by contributing to arrhythmias,   
hypertension, and atherosclerotic plaque 
develop  ment and rupture (Briones and Touyz 
2010; Dzau et al. 2006; Van Wagoner 2008).
Table 1. Assessment of the biological plausibility of MeHg-related MI.
Epidemiological Animal In vitro
Effects No. of studies Strength of evidence No. of studies Strength of evidence No. of studies Strength of evidence Overall
Oxidation Few Weak to moderate Few Moderate to strong Some Weak Moderate to strong
Atherosclerosis/IMT Some Moderate None NA None NA Moderate
HRV Some Strong NA NA NA NA Strong
BP/hypertension Some Weak to moderate Few Weak NA NA Weak
Fatal and nonfatal MI Some Moderate None NA NA NA Moderate
Biological plausibility 
for MI considering 
intermediary effects
Moderate to strong
Abbreviations: BP, blood pressure; Few, 1–3 studies; IMT, intima-media thickness; MI, myocardial infarction. NA, not applicable; Some, 4–12 studies. Workshop participants used pro-
fessional judgment to qualitatively evaluate the strength of evidence associated with each effect.Cardiovascular effects of methylmercury exposures
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Multiple hypotheses concerning the abil-
ity of MeHg to induce oxidative stress have 
been proposed (Salonen et al. 1995). These 
involve either direct effects of MeHg, where 
it catalyzes reactions that produce ROS, pos-
sibly generated during its metabolism to inor-
ganic Hg, or indirect effects of MeHg, where 
it binds to sulfhydryl groups or selenium and 
inactivates antioxidant thiol compounds or 
peroxide-  scavenging enzymes such as glutathi-
one peroxidase (Grotto et al. 2009; Khan and 
Wang 2009).
Two epidemiological studies support a link 
between MeHg exposure and oxidative stress. 
Salonen et al. (1995) reported elevated MeHg 
levels associated with increased levels of oxidized 
low-density lipoprotein (LDL) in serum from a 
subset of a cohort of Finnish men. In a study of 
Amazonian communities with high fish con-
sumption, Grotto et al. (2010) found signifi-
cant associations between biomarkers of MeHg 
exposure (blood Hg and hair Hg) and markers 
of oxidative stress (e.g., glutathione, glutathi-
one peroxidase, and catalase). However, a study 
conducted in Quebec, Canada, before and after 
the freshwater sport fishing season in James Bay 
showed that oxidized LDL decreased by about 
20% and antioxidants increased slightly in fish-
ermen, despite a doubling of hair Hg levels over 
the same period (Bélanger et al. 2008).
Animal studies have consistently found evi-
dence for MeHg-induced oxidative stress. For 
instance, MeHg has been shown to increase 
lipid peroxidation in rats (Huang et al. 1996; 
Lin et al. 1996). In addition, Grotto et al. 
(2009) found that long-term, low-dose expo-
sure to MeHg increased production of ROS 
in rats as inferred from increased production 
of malondialdehyde (a secondary product of 
lipid peroxidation and a biomarker of cell 
membrane injury), depletion of glutathione, 
and depressed nitrogen oxide bioavailability (a 
marker of endothelial dysfunction).
In vitro evidence mostly supports an indi-
rect mechanism for MeHg-related oxidative 
stress. Gatti et al. (2004) found MeHg toxic-
ity in vitro via glutathione depletion, with 
little evidence of increased ROS. Similarly, 
Seppänen et al. (2004) found no evidence 
for promotion of direct lipid peroxidation by 
MeHg. Other in vitro studies have provided 
support for the hypothesis that MeHg can 
interfere with signal transduction and proper 
endothelial cell function [both in human 
umbilical cord endothelial cells (Hagele et al. 
2007; Mazerik et al. 2007; Peltz et al. 2009) 
and bovine endothelial cells (Kishimoto et al. 
1995; Ohno et al. 1995)], which may influ-
ence atherosclerosis. However, three studies 
support a direct mechanism for MeHg’s role 
in oxidation, showing that antioxidants and 
compounds that remove ROS can mitigate 
MeHg toxicity (Gasso et al. 2001; Park et al. 
1996; Welsh 1979).
Although the specific mechanism for 
MeHg’s role in oxidative stress is uncertain, 
we found the evidence for MeHg-induced oxi-
dation to be “moderate to strong,” based on 
the strength of the available epidemiological 
and animal studies.
Atherosclerosis. Most acute MIs are caused 
by the blockage of a coronary artery, leading to 
ischemia and heart cell death. Atherosclerosis 
can directly limit blood flow in these arteries 
through significant plaque buildup and release 
of vasoconstrictors (Vander et al. 2001). Blood 
clots can also form in the plaque, detach, and 
lead to a blockage.
One possible pathway for MeHg’s effects 
on atherosclerosis is through oxidative 
stress, as described above. Another possibil-
ity explored through in vitro studies is that 
MeHg influences adhesion molecules, which 
promote atherosclerosis by attracting white 
blood cells to the endothelium of the artery 
(Prozialeck et al. 2002).
Epidemiological studies that have explored 
a link between MeHg and atherosclerosis 
generally focus on the intima-media thick-
ness (IMT) of the carotid artery, a common 
measure for assessing the progression of athero-
sclerosis (Stein et al. 2008). Three epidemio-
logical studies support a link between MeHg 
exposure and increased IMT. The first, a study 
of Faroese whaling men, found that MeHg 
exposure biomarkers were significantly asso-
ciated with increased IMT, with toenail Hg 
being the best predictor (Choi et al. 2009). In 
a study of Finnish men, those in the highest 
quintile of hair Hg exhibited a 32% increase 
in mean carotid IMT compared with those in 
all other quintiles (Salonen et al. 2000). IMT 
also increased with increasing Hg levels among 
Nunavik Inuit adults in Quebec (Dewailly 
et al. 2009). However, in a fourth study of a 
cohort of Indian Cree adults, Hg was not asso-
ciated with changes in IMT (Viger et al. 2007).
Based on the plausibility of the mechanisms 
for the effects of MeHg on athero  sclerosis and 
the generally supportive epidemiological evi-
dence, we classify the strength of the IMT end 
point as “moderate.”
Heart rate variability. HRV is an indicator 
of the dynamic adaptation capacity of the car-
diac system and is a measure that is commonly 
used in epidemiological studies to evaluate 
autonomic nervous function. Decreased HRV 
is a common feature of cardiovascular disease 
and predicts increased risk of cardiovascular 
mortality, particularly in the elderly (Hattis 
2003; Lahiri et al. 2008). It is possible that this 
mechanism works through MeHg toxicity to 
the neurological system, because autonomic 
function is governed by the central nervous sys-
tem; however, specific evidence of this mecha-
nism is lacking at the dose levels of interest.
Existing epidemiological literature consis-
tently shows a decrease in HRV with MeHg 
exposure, although the specific measures of 
HRV in each study vary. In a recent inter-
vention study, Yaginuma-Sakurai et al. (2009), 
randomly assigned a sample of healthy Japanese 
adults to either an experimental group, in 
which the participants were exposed to MeHg 
for 14 weeks at Japan’s provisional tolerable 
weekly intake for adults by consuming appro-
priately sized meals of tuna and swordfish, or 
to a control group. In the experimental group, 
hair Hg increased by nearly a factor of 4, and 
HRV (specifically the sympathovagal balance 
index) decreased significantly. After a 15-week 
“washout” period, HRV measurements in the 
experimental group returned to baseline. These 
results suggest that moderate dietary intake of 
MeHg over relatively short periods can induce 
sympathodominant states (reflecting either 
reduced vagal or elevated sympathetic activ-
ity) that reduce HRV. However, the very 
long half-life of MeHg observed in this study 
(mean = 105 days) makes interpretation of 
this study somewhat uncertain.
HRV decreased with increasing MeHg 
in a study of Nunavik Inuit adults in Canada 
(Valera et al. 2008). Studies of Cree Indians 
and Polynesian populations also showed simi-
lar results (Valera et al. 2009a, 2010). In a 
study of those living near an industrial com-
plex in Korea, HRV decreased > 8% per 
1-ppm increase in hair Hg levels (Lim et al. 
2009). However, the Faroese whaling study by 
Choi et al. (2009) reported that the effects of 
MeHg on HRV were equivocal.
These associations have also been observed 
in children (Grandjean et al. 2004; Murata 
et al. 2006; Sørensen et al. 1999), although 
the direct significance of decreased HRV 
in young children for later development of 
  cardiovascular disease is unknown.
Although the specific mechanism for the 
effects of MeHg on HRV has not been eluci-
dated, we found that the epidemiological lit-
erature is generally consistent in reporting an 
association between MeHg and HRV, which 
led us to classify the evidence supporting this 
end point as “strong.”
Blood pressure and hypertension. 
Increased blood pressure (BP) or hyperten-
sion can enhance the development of athero-
sclerosis and MI. In addition, hypertension 
is a cardiovascular health end point in and of 
itself that can also lead to other health prob-
lems such as heart failure, kidney damage, or 
stroke (Lawes et al. 2008).
Several studies have found evidence of a 
link between MeHg and increased measures 
of BP, although the specific measure var-
ies from study to study. Two studies found a 
positive association between MeHg exposure 
and systolic blood pressure (SBP): a study of 
Inuit adults (Valera et al. 2009b) and a study of 
individuals from the Brazilian Amazon (Fillion 
et al. 2006). In addition, two studies report Roman et al.
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positive associations between MeHg exposure 
and increased diastolic blood pressure (DBP): 
the Faroese whaling men study by Choi et al. 
(2009) and a study in a Philippine gold min-
ing community (Cortes-Maramba et al. 2006). 
However, the latter study may include Hg 
intake via routes other than fish and through 
forms of Hg other than MeHg (e.g., docu-
mented storage of elemental Hg in homes). 
Results from studies in French Polynesia were 
suggestive of a positive association with both 
SBP and DBP, but the association was not sig-
nificant (Valera et al. 2009a). Finally, a study 
of 24-hr ambulatory BP in samples of Danes 
and Greenlanders found that blood Hg was 
positively correlated with pulse pressure only 
(Pedersen et al. 2005).
MeHg and BP associations have also been 
identified in children. In the Faroese cohort, 
Sørensen et al. (1999) observed associations 
among children between increased SBP and 
DBP and prenatal MeHg exposure at the 
7-year evaluation. A study of children from 
the Seychelles Child Development Study, who 
were tested at 12 and 15 years of age, found 
increased DBP in 15-year-old boys prenatally 
exposed to MeHg (Thurston et al. 2007).
Studies that did not find increased BP 
with increased MeHg included another study 
of Amazonian Indians (Dórea et al. 2005) 
that found a trend of smaller increases in 
BP with age among higher fish consumers. 
A study of Saudi Arabian women (Al-Saleh 
et al. 2006) reported no association between 
hypertension and Hg; however, this study 
used serum Hg as a biomarker, which largely 
reflects inorganic Hg exposure. In addition, 
the previously observed effect on BP was not 
found in children of the Faroese cohort at the 
14-year follow-up (Grandjean et al. 2004).
In animal studies, long-term exposure to a 
low dose of MeHg (100 μg/kg/day) increased 
SBP in Wistar rats (Grotto et al. 2009); these 
results are consistent with the results of other 
studies in rats that administered higher doses 
(Tamashiro et al. 1986; Wakita 1987).
Because of the inconsistency in the results 
of the epidemiological studies in terms of the 
specific BP measure affected in humans and 
whether a link was found with MeHg expo-
sure, we found the evidence for MeHg’s effect 
on BP to be “weak.”
Myocardial infarction. Four major epidemi-
ological studies published in the last decade have 
examined the direct association between MeHg 
exposure through fish consumption and risk 
of MI: the European Community Multicenter 
Study on Antioxidants, Myocardial Infarction 
and Breast Cancer (EURAMIC; Guallar et al. 
2002), the Kuopio Ischaemic Heart Disease 
Risk Factor (KIHD) study (Virtanen et al. 
2005), the Health Professionals Follow-up 
Study (HPFS; Yoshizawa et al. 2002), and the 
Northern Sweden Health and Disease Study 
(NSHDS; Hallgren et al. 2001). Table 2 gives a 
detailed summary of these key studies.
EURAMIC and the KIHD study both 
report significant positive associations between 
MeHg exposure and MI incidence. Strengths 
Table 2. Summary of the epidemiological literature on the effects of MeHg on the incidence of MI.
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First nonfatal MI Toenail DHA in adipose 
tissue
After controlling for DHA and a number 
of risk factors for heart disease, the 
authors reported an OR of 2.16 (95% CI, 
1.09–4.29; p-value for trend = 0.006) 
comparing the highest quintile of toenail 
Hg level with the lowest. 
A positive monotonic increase in the risk 
of MI exists with toenail Hg content 
> 0.25 μg/g. Slope increases with 
adjustment for adipose tissue DHA 
content. The OR associated with a change 
from the 25th to the 75th percentile of 
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After controlling for several cardiovascular 
disease risk factors and DHA and DPA 
levels, men in the highest third of hair 
Hg content had a 1.60-fold (95% CI, 
1.24–2.06) increased risk of an acute 
coronary event, compared with the two 
lower thirds combined. 
On average, the risk of an acute coronary 
event increased by 11% for each 1-μg/g 





USA Male health 
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In a multivariate analysis, the RR of 
nonfatal MI or fatal CHD for men in 
the highest versus the lowest quintile 
of toenail Hg level was 1.04 (95% CI, 
0.65–1.68; p-value for trend = 0.68). 
An analysis excluding dentists found 
an elevated, although nonsignificant, 
association (RR = 1.70; 95% CI, 
0.78–3.73; p-value for trend = 0.41). 
The authors note that this supplemental 
analysis included a smaller number of 
cases (220) and therefore is associated 





Sweden Men and women 30, 
40, 50, or 60 years 




First MI (fatal or 
nonfatal)
Erythrocytes  EPNA and 
DHA in plasma 
phospholipids
Inverse association found between Ery-Hg 
concentration and risk of MI (RR = 0.51; 
95% CI, 0.21–1.24) comparing high versus 
low Ery-Hg groups.
Abbreviations: CHD, coronary heart disease; CI, confidence interval; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPNA, eicosapentaenoic acid; ERY-Hg, erythrocyte Hg; 
OR, odds ratio. 
aThis included definite and probable MI and typical prolonged chest pain episodes.Cardiovascular effects of methylmercury exposures
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of these two studies include their relatively 
large sample sizes, control for a number of key 
potential confounders, and inclusion of only 
first MI, reducing the likelihood that patients 
had changed their diet before the event. 
Additional strengths of EURAMIC include 
exposure data that were collected shortly 
after the MI, reducing the possibility that the 
measure  ments were affected by the develop-
ment of disease, and recruitment of partic-
ipants across eight European countries and 
Israel, resulting in a wide range of MeHg and 
fish oil intake (Guallar et al. 2002). Additional 
strengths of the KIHD study include its pro-
spective design, population-based recruitment, 
homogeneous study population, limited loss 
to follow-up, and a diet of mostly nonfatty 
freshwater fish, which reduces the possibility of 
confounding by cardioprotective compounds 
that are correlated with fat composition of fish.
The HPFS did not find an association 
between MeHg and MI when analyzing the 
entire study population. However, the HPFS 
measured fatty acid intake through a question-
naire on fish consumption, which may lead to 
residual confounding due to the potential 
inaccuracies of the semiquantitative food fre-
quency questionnaire as opposed to direct 
measurement. In addition, the results could 
be confounded by occupational inorganic Hg 
exposure in dentists, who comprise almost 
half of the study population. Excluding den-
tists from the analysis resulted in an elevated, 
although nonsignificant, association (Table 2). 
Yoshizawa et al. (2002) note that this supple-
mental analysis included a smaller number 
of cases (220) and therefore lacks sufficient 
statistical power to detect an effect.
In the NSHDS, Hallgren et al. (2001) 
reported an inverse association between 
MeHg and MI. However, this study suf-
fers from small sample size (78 cases), the 
potential for exposure misclassification [for 
example, a single measurement of erythro-
cyte Hg (Ery-Hg) taken at enrollment—up to 
10 years before the MI—may not accurately 
represent long-term exposures of concern], 
and an exposure gradient that is potentially 
too narrow to detect an association. Only two 
subjects in this study had Ery-Hg levels that 
corresponded to hair Hg levels > 2 μg/g, the 
level above which the KIHD study found 
positive effects (Virtanen et al. 2007).
Overall, we believe the link between 
MeHg and MI is plausible, given the range 
of intermediary effects for which some posi-
tive evidence exists and the strength and con-
sistency across the epidemiological studies 
for MI. Figure 1 illustrates this consistency, 
showing significant overlap between the 
effect estimates from the four major studies 
of MI. Three of the four studies have relative 
risks (RRs) that are elevated and somewhat 
clustered (these RRs fall between ~ 1.5 and 
2.0), with overlapping confidence bounds. 
However, some uncertainty remains as to 
whether a causal relationship exists because of 
ambiguity in the specific biological mechanism 
involved, the small number of epidemiological 
studies, and inconsistencies in the literature 
supporting some of the intermediary effects 
(e.g., BP). Therefore, as a group, we found the 
evidence of MI to be “moderate to strong.” 
During the workshop, the individual authors 
provided quantitative estimates of the likeli-
hood of a true causal relationship between 
MeHg and MI that ranged from 0.45 to 0.80.
Recommended cardiovascular end points 
to include in benefits assessments. In making 
recom  mendations on cardiovascular end points 
for inclusion in an MeHg benefits assessment, 
we considered both the strength of evidence 
linking the outcome with MeHg and whether 
it has sufficient clinical specificity that changes 
in incidence could be estimated and economic 
valuation could be applied. We considered 
two of the five cardio  vascular end points to 
satisfy the latter condition: hyper  tension and 
acute MI. However, of the two, we believe 
that only MI has sufficient evidence to support 
its inclusion in a benefits assessment, based on 
both the current evidence linking MeHg to 
MI directly and the influence of MeHg on 
intermediary effects leading to MI. Therefore, 
we recommend that future benefits analyses of 
MeHg reductions include a quantification of 
avoided cases of MI in adults.
Other recommendations for developing 
a dose–  response function. Below, we provide 
recommendations on key factors relating to 
the derivation of a dose–  response function 
relating MeHg exposure with MI.
Epidemiological evidence. Of the four 
main studies that examined the MeHg–MI 
relationship, we believe EURAMIC and the 
KIHD study provide the strongest and most 
useful data sets for quantifying MeHg-related 
incidence of MI for benefits assessment 
because of their strengths outlined above. 
The methodological issues associated with the 
HPFS and NSHDS, discussed in the preced-
ing section, limit the usefulness of these stud-
ies for deriving a dose–  response function for 
benefits assessment.
Exposure metric. For the purposes of an 
MeHg regulatory benefits analysis centered on 
the MI outcome, where the toxicity of MeHg 
is likely to operate over long periods of expo-
sure, the use of hair Hg or toenail Hg may 
prove to be more useful than blood Hg. These 
two biomarkers allow for an assessment of a 
longer-term average Hg concentration that 
may be more pertinent for mechanisms lead-
ing to MI (e.g., increased IMT over time).
Shape of the dose–  response function. 
Many of the existing MI epidemiological 
studies include Hg biomarker concentration 
as a categorical variable (e.g., quintiles of bio-
marker concentration). However, EURAMIC 
used generalized additive models (GAMs) to 
Figure 1. Consistency and strength of association for Hg–cardiovascular risks: RRs and odds ratios (ORs). 
Abbreviations: CI, confidence interval; Max, maximum hair Hg. Adapted from Rice et al. (2010). “Swedish” 
results refer to NSHDS. The plot of the HPFS (“Health Professionals”) represents the results of a sepa-
rate multivariate analysis (n = 220) excluding subjects likely exposed occupationally to inorganic Hg (i.e., 
dentists). To convert toenail Hg levels reported in EURAMIC and HPFS to hair Hg levels, Rice et al. (2010) 
used the regression model developed by Ohno et al. (2007) from an analysis excluding women with artificial 
hair waving. To convert the Ery-Hg concentrations reported in NSHDS to hair Hg, Rice et al. (2010) first esti-
mated the corresponding Hg levels expected in whole blood by multiplying the concentration of Hg in the 
erythrocytes by the specific gravity of erythrocytes (1,093 g/L) and the average male hematocrit (46%). They 
then used data from the World Health Organization that measured the distribution of MeHg between human 
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help elucidate the shape of the dose–  response 
function (Guallar et al. 2002; Hastie and 
Tibshirani 1990). This analysis suggested a 
roughly linear relationship between log-
transformed toenail Hg concentrations and 
the log odds of MI (see Figure 2). Reanalysis 
of the KIHD data set using flexible dose– 
response models such as GAM or spline 
regression models would provide a consistent 
basis for the evaluation of the shape of the 
dose–  response function across studies [for fur-
ther information on GAMs, see Supplemental 
Material (doi:10.1289/ehp.1003012)].
Confounding and effect modification. 
One important factor to consider when 
deriving a dose–  response function for the 
MeHg–MI relationship is the potential for 
“negative confounding” by the presence of 
n-3 polyunsaturated fatty acids (PUFAs) in 
the fish consumed (i.e., docosapentaenoic, 
docosahexaenoic, and eicosapentaenoic acids). 
Negative confounding refers to a factor result-
ing in an underestimate of the true effect if 
not properly controlled (Choi et al. 2008). 
PUFAs are found largely in oily, cold-water 
fish, such as salmon and herring (Mahaffey 
et al. 2008). These compounds have been 
linked to a decreased risk of cardiovascu-
lar disease (Mozaffarian and Rimm 2006). 
Therefore, it is important that the coefficient 
for an MeHg–MI dose–  response function be 
derived from a model that fully controls for 
confounding by PUFAs, in order to avoid 
introducing bias into the estimates.
To date, existing epidemiological stud-
ies have controlled for this confounder by 
assuming a linear relationship between PUFAs 
and risk of MI. However, the association 
between PUFA intake and cardiovascular risk 
may not be linear (Mozaffarian and Rimm 
2006). Therefore, going forward, we recom-
mend reanalysis of the epidemiological data 
to incorporate nonlinear adjustments for this 
negative confounder in order to reduce the 
possibility of an artificially attenuated dose– 
response coefficient [for more information, 
see Supplemental Material (doi:10.1289/
ehp.1003012)].
Another consideration in the derivation of 
the dose–  response function is possible effect 
modification by cardioprotective compounds. 
We found mixed results in epidemiological 
studies that assessed the possibility of effect 
modification through the use of interaction 
terms. EURAMIC and HPFS do not support 
effect modification by PUFAs or selenium, 
respectively, whereas the KIHD study did 
find a statistically significant interaction term 
between MeHg exposure and PUFAs. At 
this time, the evidence is insufficient to con-
clude whether effect modification by cardio-
protective compounds occurs, because of the 
inconsistent results across the epidemiological 
studies and the lack of mechanistic evidence. 
In addition, differentiating between effect 
modification by cardioprotective compounds 
and a nonlinear dose–  response function can 
be difficult when exposure is moderately to 
highly correlated with a confounder.
Definition of outcome. Another key 
question is whether separate dose–  response 
functions can or should be estimated for fatal 
and nonfatal MIs. Three of the epidemiologi-
cal studies—KIHD, HPFS, and NSHDS—
provide risk estimates for total MI, including 
both fatal and nonfatal outcomes. EURAMIC 
provides a RR for nonfatal MIs. At this time, 
we believe there is insufficient evidence to con-
struct separate dose–  response functions for fatal 
and nonfatal MIs. Therefore, we recommend 
that a single dose–  response function from the 
existing literature be derived that would repre-
sent total MIs. Data on the survivability of MIs 
could then be used to determine the fraction of 
avoided MeHg-related MIs that would be fatal 
versus nonfatal in a   benefits assessment.
Pooling across studies. When deriv-
ing an MeHg–MI dose–  response function, 
it may be useful to pool across the two rec-
ommended studies, EURAMIC and KIHD, 
to increase statistical power and widen the 
range of exposure levels to which the dose– 
response function could be applied. One way 
to pool the data from these two studies would 
be to convert the exposure data to a single 
biomarker. This can be achieved through the 
use of biomarker ratios. If the assumption is 
made that MeHg consumption occurs with a 
sufficiently high frequency over a long period 
of time to allow the body burden of MeHg to 
reach approximate steady state, it is possible 
to derive hair-to-blood, hair-to-toenail, or 
toenail-to-blood ratios (Bartell et al. 2000). 
Multiple studies have attempted to calculate 
these ratios (e.g., Bjorkman et al. 2007; Choi 
et al. 2009; Ohno et al. 2007). However, a 
large amount of variability and uncertainty 
is associated with these values, stemming 
from the significant interindividual variabil-
ity in toxicokinetics of MeHg (NRC 2000), 
evidence of laboratory measurement error 
(Bartell et al. 2000), and uncertainty about 
the assumption of steady-state conditions and 
the temporal association between exposure 
and Hg measurement (i.e., blood and hair 
samples obtained at the same time do not 
yield Hg exposure values that reflect identical 
exposure time periods).
Another approach would be to assume 
that the log of the odds of an MI is, over the 
range of exposures in the general population, 
proportional to the logarithm of MeHg expo-
sure. If this is true, and these models were 
refit for the two recommended studies, then 
the coefficients would be interpretable as 
the percent change in the odds of an MI for 
a given percentage change in the exposure 
metric. However, it would be necessary to 
explore whether there is biological justifica-
tion for altering the functional form of the 
relationship between exposure and effect in 
this way. It may be worthwhile to analyze 
the data using both of these approaches to 
help characterize uncertainty in the analysis, 
because each method is subject to different 
sources of error.
To determine whether pooling of these 
two studies is reasonable, we examined the Hg 
levels of the study populations in these two 
studies by converting them to the same bio-
marker using a steady-state ratio from Ohno 
et al. (2007) (2.44 μg Hg/g hair per μg Hg/g 
toenail). The results of this conversion lead us 
to believe that the exposure levels across the 
Figure 2. Nonparametric odds ratios (ORs) of MI by level of toenail Hg from EURAMIC. DHA, docosa-
hexaenoic acid. The right-hand y-axis indicates the number of subjects in each bin of toenail Hg concen-
tration. From Guallar et al. (2002);. reproduced with permission from the New England Journal of Medicine, 
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two groups of study participants cover a range 
of values along the distribution of MeHg 
exposure in adults, and therefore it is reason-
able to pool the results. [The mean hair Hg in 
the KIHD study is 1.9 μg/g compared with a 
mean of 0.66 μg/g in EURAMIC, with the 
individual study centers in that study ranging 
from 0.34 to 1.66 μg/g; for further details, 
see Supplemental Materials (doi:10.1289/
ehp.1003012).]
Recommendations for applying the dose– 
response function in benefits assessment. The 
current MeHg–MI epidemiological stud-
ies include mostly middle-age and elderly 
men. Therefore, it is uncertain whether a 
dose–  response function derived for this sub-
population would be generalizable to women. 
Despite the limited number of studies of 
MeHg and MI in women, there is an over-
whelming body of cardiovascular research in 
which risk factors for cardiovascular disease 
are largely similar for men and women, with 
high generalizability of findings between sexes 
(Mosca et al. 2004). Thus, it appears plau-
sible that MeHg-related MIs could occur in 
women as well as men. Therefore, we recom-
mend that a dose–  response function derived 
from the current epidemiological literature be 
applied to both men and women in a benefits 
assessment. However, the size of the impact in 
women would be considerably more uncertain 
than that found in men, given the paucity of 
the direct empirical data.
Another important consideration for bene-
fits assessment is whether the exposure levels 
experienced by the populations in the recom-
mended epidemiological studies are compa-
rable with exposure levels in general U.S. 
population. We found that the hair Hg levels 
in EURAMIC and the KIHD study corre-
spond to the upper end of the distribution 
of hair Hg in women of childbearing age in 
the United States [~ 75th–95th percentile; 
for further detail, see Supplemental Material 
(doi:10.1289/ehp.1003012)]. Therefore, con-
sideration could be given to restricting appli-
cation of the dose–  response function derived 
from these studies to only those with higher 
end exposures (i.e., include a possible thresh-
old for MeHg toxicity). However, there is 
some evidence supporting a log-linear dose– 
response function (e.g., the GAM analysis in 
EURAMIC). If the relationship is in fact log-
linear, it would be appropriate to apply a single 
slope across all levels of MeHg exposure.
Future Research Needs
There is a need to expand the literature base 
describing the cardiovascular effects of MeHg. 
The workshop highlighted the following 
  specific priorities.
Additional epidemiological studies. 
Additional epidemiological studies of the 
relationship between MeHg biomarkers and 
MI are critical for helping to address whether 
there is a causal relationship underlying these 
reported associations. Such studies could also 
reduce uncertainties related to quantifying the 
MeHg–MI dose–  response function.
Dose–response assessment. A primary con-
cern for reducing uncertainty in the applica-
tion of an MeHg–MI dose–  response function 
to the general U.S. population is the need to 
expand the database of the effects of MeHg lev-
els on MI risk in general, especially in women, 
in minorities, and in patients who have pre-
existing cardiovascular disease. Additionally, 
we recommend further research into possible 
effect modification of the MI effect by sele-
nium and by diabetes status, the latter of which 
can evaluate whether persons with diabetes 
represent a sensitive subpopulation.
Research on mechanisms. Available stud-
ies do not yet provide a clear picture of the 
biological mechanisms underlying the cardio-
vascular effects observed in toxicological and 
epidemiological studies.
Exposure assessment. There is a need to 
identify existing data sets or collect and ana-
lyze new data that measure multiple biomark-
ers of Hg in individuals concurrently and 
repeatedly over the course of a year or longer. 
These data will help to better characterize or 
reduce exposure misclassification resulting 
from intraindividual variability over time in 
individual biomarkers. They will also improve 
the scientific understanding of the relation-
ships between different biomarkers and help 
to reduce uncertainty in biomarker ratios. 
Future epidemiological studies would greatly 
benefit by incorporating multiple biomarkers. 
This would help refine dose–  response rela-
tionships by allowing the use of the expo-
sure metric that provided the most robust 
statistical outcome, and by permitting the use 
of approaches that integrate these multiple 
measures such as structural equation models 
[for further detail, see Supplemental Materials 
doi:10.1289/ehp.1003012)].
Timing of benefits. At this time, little is 
known about how quickly MI risk or other 
cardiovascular risk factors may decrease after 
reductions in MeHg exposure. Yaginuma-
Sakurai et al. (2009) suggest that recovery 
of HRV from short-term spikes is relatively 
quick, but similar types of intervention studies 
that explore the effects of reductions in MeHg 
intake on cardiovascular risk factors in chronic 
consumers of high MeHg fish species would be 
particularly informative for benefits analyses.
Other cardiovascular end points. Currently, 
there is a lack of studies examining a possible 
link between MeHg exposures and risk of sud-
den cardiac death, peripheral arterial disease, 
and heart failure and very limited data on 
the link between MeHg exposure and stroke 
(Wennberg et al. 2007), all of which are 
related to some of the risk factors examined 
in this article (e.g., hypertension and athero-
sclerosis). Therefore, these are important end 
points to include in future studies on the car-
diovascular effects of MeHg.
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